We are live on
!
Find out more
Two Sigma Advisers Portfolio holdings
AUM
$51.4B
1-Year Est. Return
31.07%
This Fund
S&P 500
This Quarter
Est. Return
-2.68%
1 Year Est. Return
+31.07%
3 Year Est. Return
+128.94%
5 Year Est. Return
+161.75%
10 Year Est. Return
+607.04%
AUM
$39B
AUM Growth
-$220M
(-0.56%)
Cap. Flow
+$1.59B
Cap. Flow
% of AUM
4.06%
Top 10 Holdings %
Top 10 Hldgs %
16.38%
Holding
2,663
New
306
Increased
844
Reduced
1,189
Closed
301
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$592M |
| 2 |
Tesla
TSLA
|
+$492M |
| 3 |
Amazon
AMZN
|
+$474M |
| 4 |
Advanced Micro Devices
AMD
|
+$410M |
| 5 |
Qualcomm
QCOM
|
+$358M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SCHW
Charles Schwab
SCHW
|
+$393M |
| 2 |
Union Pacific
UNP
|
+$363M |
| 3 |
Walmart Inc
WMT
|
+$239M |
| 4 |
Citigroup
C
|
+$192M |
| 5 |
ConocoPhillips
COP
|
+$172M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.84% |
| 2 | Healthcare | 15.27% |
| 3 | Consumer Discretionary | 13.96% |
| 4 | Industrials | 10.47% |
| 5 | Financials | 8.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADAP
2276
DELISTED
Adaptimmune Therapeutics
ADAP
| $50.3K | ﹤0.01% |
64,437
-32,500
| -34% | -$27.3K |
|
|
VCSA
2277
DELISTED
Vacasa, Inc. Class A Common Stock
VCSA
| $50.3K | ﹤0.01% |
5,450
+1,235
| +29% | +$15K |
|
|
HEPS
2278
D-Market Electronic Services & Trading
HEPS
$1.06B
| $50.1K | ﹤0.01% |
37,700
-77,600
| -67% | -$119K |
|
|
SUPV
2279
Grupo Supervielle
SUPV
$842M
| $50K | ﹤0.01% |
22,500
-26,100
| -54% | -$74.9K |
|
2280
Karyopharm Therapeutics
KPTI
$161M
| $47.2K | ﹤0.01% |
2,347
-15,000
| -86% | -$337K |
|
2281
Protara Therapeutics
TARA
$221M
| $46.5K | ﹤0.01% |
27,818
-3,500
| -11% | -$8.02K |
|
2282
Lineage Cell Therapeutics
LCTX
$267M
| $46.1K | ﹤0.01% |
39,100
-10,499
| -21% | -$14.3K |
|
2283
Aquestive Therapeutics
AQST
$472M
| $46.1K | ﹤0.01% |
30,100
+1,700
| +6% | +$2.92K |
|
2284
Dominari Holdings
DOMH
$54.5M
| $45.7K | ﹤0.01% |
19,700
-900
| -4% | -$2.55K |
|
2285
Heron Therapeutics
HRTX
$92M
| $44.8K | ﹤0.01% |
43,500
-18,000
| -29% | -$25.6K |
|
|
CIO
2286
DELISTED
City Office REIT
CIO
| $44.6K | ﹤0.01% |
+10,500
| New | +$54K |
|
2287
Cumberland Pharmaceuticals
CPIX
$102M
| $44.6K | ﹤0.01% |
23,600
| – | – |
|
2288
BioRestorative Therapies
BRTX
$6.79M
| $44K | ﹤0.01% |
24,600
-1,700
| -6% | -$4.29K |
|
2289
Goldgroup Mining Inc.
GORO
$152M
| $43.3K | ﹤0.01% |
101,100
+38,900
| +63% | +$20.8K |
|
|
RENT
2290
Rent the Runway
RENT
$119M
| $42.3K | ﹤0.01% |
3,110
-180
| -5% | -$5.13K |
|
2291
Advantage Solutions
ADV
$542M
| $40.9K | ﹤0.01% |
+576
| New | +$38.2K |
|
2292
GSI Technology
GSIT
$211M
| $39.6K | ﹤0.01% |
+14,600
| New | +$56.7K |
|
2293
Acacia Research
ACTG
$447M
| $39.4K | ﹤0.01% |
10,800
-21,700
| -67% | -$83K |
|
|
NSLR
2294
Neostellar Capital Corp
NSLR
$269M
| $39.3K | ﹤0.01% |
10,848
-55,888
| -84% | -$207K |
|
2295
Blend Labs
BLND
$433M
| $38.9K | ﹤0.01% |
28,400
+1,700
| +6% | +$2.06K |
|
|
APLT
2296
DELISTED
Applied Therapeutics
APLT
| $38.8K | ﹤0.01% |
15,600
-91,071
| -85% | -$150K |
|
2297
Lexicon Pharmaceuticals
LXRX
$1.04B
| $38K | ﹤0.01% |
+34,844
| New | +$61.1K |
|
2298
ESS Tech
GWH
$22.1M
| $35.7K | ﹤0.01% |
1,267
-486
| -28% | -$11.8K |
|
2299
Barnes & Noble Education
BNED
$451M
| $35.4K | ﹤0.01% |
325
-66
| -17% | -$8.93K |
|
|
LILM
2300
DELISTED
Lilium N.V. Class A Ordinary Shares
LILM
| $34.6K | ﹤0.01% |
48,500
+12,300
| +34% | +$14.4K |
|
Similar funds
CWM
VRS
FAF
BGIM
CIM
PPFA
Two Sigma Advisers's Q3 2023 Portfolio in Review
As of Q3 2023, Two Sigma Advisers held 2,663 positions worth $39B, down 0.56% from $39.3B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Two Sigma Advisers deployed $1.59B of net new capital in Q3 2023, opening 306 new positions and adding to 844 existing holdings. Its largest new stake was Advanced Micro Devices: 3,777,240 shares worth $388M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was Charles Schwab, an estimated $393M trimmed.
- Two Sigma Advisers's largest Q3 2023 buy was Advanced Micro Devices: 3,777,240 shares worth $388M.
- Two Sigma Advisers added most to Microsoft in Q3 2023, an estimated $592M increase.
- Two Sigma Advisers's biggest Q3 2023 reduction was Charles Schwab, cutting an estimated $393M.
- Two Sigma Advisers fully exited Uber in Q3 2023, selling an estimated $109M.
- Two Sigma Advisers's ten largest holdings make up 16% of its $39B portfolio in Q3 2023.
- Two Sigma Advisers opened 306 new positions and closed 301 in Q3 2023.
- Two Sigma Advisers's portfolio value fell 0.56% quarter-over-quarter to $39B.
Based on Two Sigma Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.